Ord Minnett had a paragraph on SZL in their research report 1 May, where they affirmed their Buy recommendation and a target price of $2.70. This was of course prior to this week's update.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%